Evidence map›Paper›PMID 32338655›Full record

ArticleJournal of visualized experiments : JoVE2020

Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion.

Andrea Comba, Patrick J Dunn, Phillip E Kish, Padma Kadiyala, Alon Kahana, Maria G Castro, Pedro R Lowenstein

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Single-cell spatial proteomics.Histology and histopathology · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cancer heterogeneity and metastasis: life at the edge.Clinical & experimental metastasis · 2022
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Andrea CombaDept. of Neurosurgery, University of Michigan Medical School; Dept. of Cell and Developmental Biology, University of Michigan Medical School; Rogel Cancer Center, University of Michigan Medical School.
Patrick J DunnDept. of Neurosurgery, University of Michigan Medical School; Dept. of Cell and Developmental Biology, University of Michigan Medical School; Rogel Cancer Center, University of Michigan Medical School.
Phillip E KishDept. of Neurosurgery, University of Michigan Medical School; Dept. of Ophthalmology & Visual Science, University of Michigan Medical School.
Padma KadiyalaDept. of Neurosurgery, University of Michigan Medical School; Dept. of Cell and Developmental Biology, University of Michigan Medical School; Rogel Cancer Center, University of Michigan Medical School.
Alon KahanaDept. of Ophthalmology & Visual Science, University of Michigan Medical School.
Maria G CastroDept. of Neurosurgery, University of Michigan Medical School; Dept. of Cell and Developmental Biology, University of Michigan Medical School; Rogel Cancer Center, University of Michigan Medical School.
Pedro R LowensteinDept. of Neurosurgery, University of Michigan Medical School; Dept. of Cell and Developmental Biology, University of Michigan Medical School; Rogel Cancer Center, University of Michigan Medical School; pedrol@umich.edu.
University of Michigan–Ann Arbor · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
VIVARIUM MODULEP30EY007003 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Antonetti · 1987 to 2026
$17.6M
Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and LeukodystrophiesR01NS076991 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Guangping Gao · 2012 to 2026
$5.7M
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic StrategiesR37NS094804 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2015 to 2021
$2.9M
Novel combined immunotherapeutic strategies for glioma: using pet dogs as a large animal spontaneous modelU01CA224160 · NCI · UNIVERSITY OF MINNESOTA · PI PLUHAR, GRACE ELIZABETH · 2017 to 2021
$2.7M
Identifying intercellular circuits driving cell phenotypes within a nicheR01CA243916 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JERUSS, JACQUELINE SARA, SHEA, LONNIE D · 2019 to 2023
$2.3M
Neuroimmunology of Malignant Brain Tumors: Innate MechanismsR01NS096756 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2016 to 2020
$2.1M
Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeuticsR01NS105556 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2018 to 2021
$1.9M
Mechanisms of glioma growth and invasion novel therapeutic strategiesR01NS082311 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2013 to 2017
$1.7M
Tuning Biomaterials-immune cell interactions for treatment of glioblastoma multiformeR01EB022563 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2016 to 2019
$1.7M
A Zebrafish model of extraocular muscle regeneration.R01EY022633 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAHANA, ALON · 2013 to 2016
$1.5M
NCATS NIH HHS UL1 TR002240NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA243916NCI NIH HHS U01 CA224160NEI NIH HHS P30 EY007003NEI NIH HHS R01 EY022633NIBIB NIH HHS R01 EB022563NINDS NIH HHS R01 NS076991NINDS NIH HHS R01 NS082311NINDS NIH HHS R01 NS096756NINDS NIH HHS R01 NS105556NINDS NIH HHS R21 NS107894NINDS NIH HHS R37 NS094804
6 · The paper itself

Abstract

Gliomas are primary brain tumors characterized by their invasiveness and heterogeneity. Specific histological patterns such as pseudopalisades, microvascular proliferation, mesenchymal transformation and necrosis characterize the histological heterogeneity of high-grade gliomas. Our laboratory has demonstrated that the presence of high densities of mesenchymal cells, named oncostreams, correlate with tumor malignancy. We have developed a unique approach to understand the mechanisms that underlie glioma's growth and invasion. Here, we describe a comprehensive protocol that utilizes laser capture microdissection (LMD) and RNA sequencing to analyze differential mRNA expression of intra-tumoral heterogeneous multicellular structures (i.e., mesenchymal areas or areas of tumor invasion). This method maintains good tissue histology and RNA integrity. Perfusion, freezing, embedding, sectioning, and staining were optimized to preserve morphology and obtain high-quality laser microdissection samples. The results indicate that perfusion of glioma bearing mice using 30% sucrose provides good morphology and RNA quality. In addition, staining tumor sections with 4% Cresyl violet and 0.5% eosin results in good nuclear and cellular staining, while preserving RNA integrity. The method described is sensitive and highly reproducible and it can be utilized to study tumor morphology in various tumor models. In summary, we describe a complete method to perform LMD that preserves morphology and RNA quality for sequencing to study the molecular features of heterogeneous multicellular structures within solid tumors.

Indexed as

AnimalsBrain NeoplasmsGliomaHumansLaser Capture MicrodissectionMiceNeoplasm InvasivenessSequence Analysis, RNAStaining and Labeling

Identifiers

PMID32338655
PMCPMC7253033
OpenAlexW3015966181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.